logo
Twitter
Discord
Email
logo
Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

NASDAQ•CPRX
CEO: Mr. Richard John Daly M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2006-11-08
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Contact Information
355 Alhambra Circle, Suite 801, Coral Gables, FL, 33134, United States
305-420-3200
www.catalystpharma.com
Market Cap
$2.75B
P/E (TTM)
13.1
40.1
Dividend Yield
--
52W High
$26.58
52W Low
$19.05
52W Range
44%
Rank32Top 23.6%
4.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$148.39M+15.30%
4-Quarter Trend

EPS

$0.43+16.22%
4-Quarter Trend

FCF

$32.44M-55.33%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Months Net Income Growth Nine months net income $161.63M, up 49.7% from $107.95M in prior year period, showing strong profitability.
Total Revenues Increased Nine months total revenues $436.38M, significantly increased versus $349.91M recognized in the comparable 2024 period.
Strong Cash Position Maintained Cash and equivalents strong at $689.89M on September 30, 2025, providing ample liquidity for operations and strategy.
AGAMREE Sales Contribution AGAMREE net product revenue $81.79M for nine months 2025, reflecting successful post-launch commercial ramp activities.

Risk Factors

FYCOMPA Generic Erosion FYCOMPA revenue declined $5.3M for nine months 2025 following May 2025 patent expiration and subsequent generic entry.
FIRDAPSE Litigation Uncertainty FIRDAPSE patent litigation against Hetero remains ongoing, creating uncertainty regarding generic market entry timing.
Reliance on Third-Party Supply Exclusive reliance on third-party contractors for manufacturing poses significant supply chain continuity risks.
Inventory Reserve Established Inventory reserve established at $0.5M for unsalable product, specifically slow-moving FYCOMPA inventory units.

Outlook

New Share Repurchase Plan New $200M share repurchase program authorized through December 31, 2026, funded by existing cash resources.
Portfolio Expansion Focus Strategy focuses on acquiring near-term accretive, clinically differentiated products across rare disease therapeutic areas.
AGAMREE Manufacturing Transition Completing validation of U.S. manufacturing site for AGAMREE is expected by the end of calendar year 2026.
Continued Commercial Investment Expect substantial SG&A expenses to continue supporting FIRDAPSE and AGAMREE commercial expansion efforts.

Peer Comparison

Revenue (TTM)

Amicus Therapeutics, Inc.FOLD
$598.70M
+21.3%
Catalyst Pharmaceuticals, Inc.CPRX
$578.20M
+25.6%
Arcutis Biotherapeutics, Inc.ARQT
$317.93M
+129.2%

Gross Margin (Latest Quarter)

IDEAYA Biosciences, Inc.IDYA
99.5%
+0.0pp
Arcutis Biotherapeutics, Inc.ARQT
91.2%
+3.5pp
Amicus Therapeutics, Inc.FOLD
87.4%
-2.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
FOLD$4.42B221.6-6.8%51.0%
BEAM$3.51B-8.3-42.9%11.5%
ARQT$3.19B-77.1-29.7%1.7%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.5%
Moderate Growth
4Q Net Income CAGR
-1.9%
Stable Profitability
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 25, 2026
|
EPS:$0.42
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 5, 2025|
    Revenue: $148.39M+15.3%
    |
    EPS: $0.43+16.2%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $146.56M+19.4%
    |
    EPS: $0.43+22.9%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 7, 2025|
    Revenue: $141.42M+43.6%
    |
    EPS: $0.47+135.0%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 26, 2025|
    Revenue: $491.73M+23.5%
    |
    EPS: $1.38+106.0%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $128.70M+25.3%
    |
    EPS: $0.37-227.6%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 7, 2024|
    Revenue: $122.71M+23.2%
    |
    EPS: $0.35-2.8%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $98.51M+15.4%
    |
    EPS: $0.20-28.6%
    Meet

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 28, 2024|
    Revenue: $398.20M+85.9%
    |
    EPS: $0.67-16.3%
    Beat